Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuation

被引：1

作者：

Martinelli, Vittorio ^{[1
]}

Dalla Costa, Gloria ^{[1
]}

Sangalli, Francesca ^{[1
]}

Colombo, Bruno ^{[1
]}

Robotti, Micaela ^{[1
]}

Moiola, Lucia ^{[1
]}

Comi, Giancarlo ^{[1
]}

机构：

[1] Osped San Raffaele, Dept Neurol, Via Olgettina 48, I-20132 Milan, Italy

来源：

MULTIPLE SCLEROSIS AND RELATED DISORDERS | 2019年 / 28卷

关键词：

Multiple sclerosis; Daclizumab; Recurrence; Treatment outcome;

D O I：

10.1016/j.msard.2018.11.034

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Daclizumab, a MS treatment targeting IL2-receptor, has been recently withdrawn following reports of immune-mediated encephalitis. We report the case of a 39-years-old woman treated with daclizumab that presented a progressive decrease in the strength at her lower limbs which further worsened after the drug was stopped. Post-treatment MRI showed more than 20 new enhancing lesions. No symptoms nor signs associated with immune-mediated encephalitis were present. Our case highlights the problem of disease course after daclizumab discontinuation and urge neurologists to strictly monitor patients discontinuing the drug in order to exclude both the occurrence of immune-mediated encephalitis and disease reactivation.

引用

页码：57 / 59

页数：3

共 50 条

[1] Disease activity after natalizumab discontinuation in multiple sclerosis: reactivation or rebound?
Borriello, G.
Prosperini, L.
Mancinelli, C.
Fubelli, F.
Gianni, C.
Marinelli, F.
Pozzilli, C.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S228 - S228
[2] Severe meningo-/encephalitis after daclizumab therapy for multiple sclerosis
Stork, Lidia
Brueck, Wolfgang
von Gottberg, Phillip
Pulkowski, Ulrich
Kirsten, Florian
Glatzel, Markus
Rauer, Sebastian
Scheibe, Franziska
Radbruch, Helena
Hammer, Eckhard
Stuerner, Klarissa H.
Kaulen, Barbara
Heesen, Christoph
Hoffmann, Frank
Brock, Sebastian
Pawlitzki, Marc
Bopp, Tobias
Metz, Imke
MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (12) : 1618 - 1632
[3] Severe cutaneous adverse event in a daclizumab-treated multiple sclerosis patient
van Rossum, Johannis A.
Peters, Marieke A. D.
van der Valk, Paul
de Jong, Brigit A.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2019, 34 : 38 - 40
[4] Age as a predictive factor of disease activity after discontinuation of Disease Modifying Treatment in Multiple Sclerosis
Soares, Mafalda Delgado
Faustino, Patricia
Sequeira, Joao
Marques, Jose Pinto
Sousa, Ana
Grine, Teresa
Mateus, Claudia
Encarnacao, Susana
Santos, Ana Catarina
Gama, Anabela
Capela, Carlos
Ladeira, Filipa
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 970 - 971
[5] Cryptococcal meningitis after fingolimod discontinuation in a patient with multiple sclerosis
Ward, Melanie D.
Jones, David E.
Goldman, Myla D.
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 9 : 47 - 49
[6] Severe encephalitis and meningoencephalitis with systemic symptoms after daclizumab therapy for multiple sclerosis.
Stork, L.
Brueck, W.
von Gottberg, P.
Pulkowski, U.
Kirsten, F.
Glatzel, M.
Rauer, S.
Scheibe, F.
Radbruch, H.
Hammer, E.
Stuerner, K. H.
Kaulen, B.
Hoffmann, F.
Brock, S.
Pawlitzki, M.
Bopp, T.
Metz, I.
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 36 - 37
[7] Safety of daclizumab discontinuation in a cohort of multiple sclerosis patients in real world monitoring
Mallucci, G.
Maregatti, M. C.
Romani, A.
Bergamaschi, R.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 671 - 671
[8] Pulmonary Sarcoidosis in a patient with Multiple Sclerosis on daclizumab monotherapy
Rhone, Elijah Edward
Cho, Peter Siu Pan
Birring, Surinder S.
Galloway, James
Silber, Eli
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 20 : 25 - 27
[9] Daclizumab in multiple sclerosis
Perez-Miralles, Francisco C.
REVISTA DE NEUROLOGIA, 2018, 66 (08) : 271 - 282
[10] Reactivation of disease activity in patients with multiple sclerosis after Natalizumab discontinuation: a case report in Venezuela
Soto, I
Ferrer, O.
Molina, O.
Mora, E.
Villalobos, V.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1860 - 1860

← 1 2 3 4 5 →